Trial Profile

Safety, Tolerability and Pharmacokinetics of NNC0487-0111 in Participants With Overweight or Obesity

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amycretin (Primary)
Indications Obesity
Focus Adverse reactions; First in man
Sponsors Novo Nordisk

Most Recent Events

20 Jun 2025 According to a Novo Nordisk Media Release, data from this study were presented in The Lancet medical journal.
20 Jun 2025 Results presented in the Novo Nordisk's Media Release.
30 Jan 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com